The Lawyer Asia Pacific 150 is the only research report to provide a ranking of the top 100 independent local firms and top 50 global firms in the region. The report offers critical review of some of the fastest growing firms and their strategies, a country-by-country guide to leading legal advisers and legal services market trends, plus exclusive insight into the current business development opportunities in the Asia Pacific. Read more
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
It’s been a busy weekend for those lawyers working in the pharmaceutical sector.
Drugs retail giant Alliance-Boots revealed late last week that it had received a friendly £9.7bn takeover approach from US private equity house Kohlberg Kravis Roberts (KKR) – another busy bee, given its mooted offer with the rest of the CVC-led consortium for J Sainsbury.
Allen & Overy (A&O) and Slaughter and May have been battling it out to be Alliance-Boots’ go-to firm ever since the Boots and Alliance-Unichem merger last year.
It’s one-nil to Slaughters, with the news that Alliance-Boots is turning to the firm for its KKR approach. And that’s one hell of an instruction. (see story)
Still, A&O shouldn’t feel too glum given that it picked up, together with Lovells, the other big pharma instruction of the last few days: Schering-Plough’s £7.5bn purchase of Dutch giant Akzo Nobel’s drugs division. (see story)